Literature DB >> 34652690

Glucose control in type 1 diabetes and COVID-19.

R Mungmunpuntipantip1, V Wiwanitkit2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34652690      PMCID: PMC8517561          DOI: 10.1007/s40618-021-01688-0

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   5.467


× No keyword cloud information.
Dear Editor, We would like to share ideas on “Glucose control in home-isolated adults with type 1 diabetes affected by COVID-19 using continuous glucose monitoring [1].” Longo et al. concluded that “Young home-isolated patients with type 1 diabetes and COVID-19 showed a worsening of …infection [1].” In general, COVID-19 can affect glucose metabolism and it might result in elevation of blood glucose and hemoglobin A1C [2]. If there is no good diabetic care during COVID-19 illness, the DM patient under home isolation might have poor glucose control. In the present report, there are many confounding factors that might affect the observation on diabetic control. The severity of COVID-19 cases might be associated with outcome and there should be subgroup analysis. Additionally, medication used by patient should be mentioned. In our setting, Asia, many COVID-19 patients use alternative therapy and it can result in high blood glucose level. Furthermore, the use of telemedical care should be discussed. Whether the telemedicine care includes specific session on diabetic care is an interesting question.
  2 in total

1.  Estimated Blood Glucose and Hemoglobin A1C in COVID-19: a Preliminary Summarization.

Authors:  Pathum Sookaromdee; Viroj Wiwanitkit
Journal:  Clin Lab       Date:  2020-09-01       Impact factor: 1.138

2.  Glucose control in home-isolated adults with type 1 diabetes affected by COVID-19 using continuous glucose monitoring.

Authors:  M Longo; L Scappaticcio; M Petrizzo; F Castaldo; A Sarnataro; D Forestiere; F Caiazzo; G Bellastella; M I Maiorino; A Capuano; K Esposito
Journal:  J Endocrinol Invest       Date:  2021-09-05       Impact factor: 4.256

  2 in total
  1 in total

1.  Reply to the letter to the editor by Mungmunpuntipantip et al.

Authors:  M Longo; M I Maiorino; K Esposito
Journal:  J Endocrinol Invest       Date:  2021-10-22       Impact factor: 5.467

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.